Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19295085 | 0.81 | DGAT1 (0.49) | LPLLIPGBACE1 | |
| SCHEMBL2012175 | 0.79 | LPL (0.44) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL16905126 | 0.79 | LPL (0.44) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL15614972 | 0.77 | LPL (0.46) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL16998416 | 0.77 | LPL (0.42) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL15614981 | 0.77 | LPL (0.42) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL2014065 | 0.76 | LPL (0.44) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL15614857 | 0.75 | LPL (0.38) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL15614863 | 0.75 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19700895 | 0.74 | LPL (0.40) | LPLLIPGBACE1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11005050-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3424936-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-20200216605-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2020-07-09 | — | — | US | disclosed |
| EP-3424936-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| EP-3094638-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-11-08 | — | — | EP | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20160365520-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160365520-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| WO-2015104045-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
| US-20150171348-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150171348-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| WO-2014023377-A2 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150171348-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | LPL 3163/4885LIPG 3210/4885BACE1 2807/4885 |
| US-11005050-B2 | Metal complexes | SOD1, AP1M1, AP3M1 | LPL 3163/4885LIPG 3210/4885BACE1 2807/4885 |
| US-20160365520-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | LPL 3163/4885LIPG 3210/4885BACE1 2807/4885 |
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | LPL 3163/4885LIPG 3210/4885BACE1 2807/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | LPL 2338/4885LIPG 2895/4885BACE1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.